Thus, based on our results and the drug’s mechanism of action, a high expression of BCL2 seems to be common in ATO APL-resistant cells but also required, in this leukemia type, for sensitivity to venetoclax, suggesting that BCL2 expression might be regarded as a biomarker of the response. Here, BCL2 is linked to leukemia.